1 Urologisk Klinik, Abdominal Centre, Rigshospitalet, The Capital Region of Denmark2 unknown
In the mid-1980s, interest in parenteral estrogen therapy for prostate cancer was renewed when it was found that it influenced liver metabolism only marginally and had very few cardiovascular side-effects. In this study high-dose polyestradiol phosphate (PEP; Estradurin) was compared to combined androgen deprivation (CAD) for the treatment of patients with metastatic prostate cancer. The aim of the study was to compare anticancer efficacy and adverse events, especially cardiovascular side-effects.
Scandinavian Journal of Urology and Nephrology, 2002, Vol 36, Issue 6, p. 405-13